Hyperforin protects against acute cerebral ischemic injury through inhibition of interleukin-17A-mediated microglial activation.
MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6 wild-type and interleukin-17A knock-outMaleIntracerebroventricular injection into the right ventricle0.5 microgram per injectionFirst dose 1 h after onset of middle cerebral artery occlusion
Model: Middle cerebral artery occlusion for 60 min followed by 72 h reperfusion
Hyperforin reduced infarct volume and improved neurologic scores at 72 h, decreased interleukin-17A expression and microglial activation and promoted M2 polarisation; recombinant interleukin-17A abolished these protective effects.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.